XML 20 R14.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue from contracts with customers
 9 Months Ended
Sep. 30, 2025
Revenue from contracts with customers
NOTE 3 – Revenue from contracts with customers:
Disaggregation of revenue
The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.
 
    
Three months ended September 30, 2025
  
    
United States
     
Europe
     
International
Markets
     
Other
activities
     
Total
  
    
(U.S.$ in millions)
  
Sale of goods
      2,063        1,207        512        125        3,907  
Licensing arrangements
      27        11        5        3        46  
Distribution
      392        §        14        —         406  
Other
      §        16        26        78        121  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
   $ 2,483      $ 1,235      $ 557      $ 205      $ 4,480  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
 
§
Represents an amount less than $0.5 million.
 
    
Three months ended September 30, 2024
  
    
United States
     
Europe
     
International
Markets
     
Other
activities
     
Total
  
    
(U.S.$ in millions)
  
Sale of goods
      1,822        1,214        568        121        3,725  
Licensing arrangements
      23        9        6        8        45  
Distribution
      380        §        10        —         390  
Other
      §        42        29        100        172  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
   $ 2,225      $ 1,265      $ 613      $ 229      $ 4,332  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
 
§
Represents an amount less than $0.5 million.
 
    
Nine months ended September 30, 2025
  
    
United States
     
Europe
     
International
Markets
     
Other
activities
     
Total
  
    
(U.S.$ in millions)
  
Sale of goods
      5,332        3,681        1,535        389        10,937  
Licensing arrangements
      78        27        20        3        128  
Distribution
      1,130        1        36        —         1,167  
Other
      3        18        43        251        314  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
   $ 6,543      $ 3,726      $ 1,634      $ 644      $ 12,547  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
 
 
    
Nine months ended September 30, 2024
  
    
United States
     
Europe
     
International
Markets
     
Other
activities
     
Total
  
    
(U.S.$ in millions)
  
Sale of goods
      4,857        3,668        1,708        399        10,632  
Licensing arrangements
      68        26        17        10        121  
Distribution
      1,134        §        28        —         1,163  
Other
      §        54        49        295        399  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
   $ 6,060      $ 3,749      $ 1,802      $ 703      $ 12,315  
  
 
 
     
 
 
     
 
 
     
 
 
     
 
 
  
§
Represents an amount less than $0.5 million.
Variable consideration
Variable consideration mainly includes sales reserves and allowances (“SR&A”), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (
including
shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables.
The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions.
SR&A to U.S. customers comprised approximately 70% of the Company’s total SR&A as of September 30, 2025, with the remaining balance primarily related to customers in Canada and Germany. The changes in SR&A for third-party sales for the nine months ended September 30, 2025 and 2024 were as follows:
 
    
Sales Reserves and Allowances
        
    
Reserves
included in
Accounts
Receivable,
net
    
Rebates
    
Medicaid and
other
governmental
allowances
    
Chargebacks
    
Returns
    
Other
    
Total
reserves
included in
Sales
Reserves
and
Allowances
    
Total
  
    
(U.S.$ in millions)
  
Balance at January 1, 2025
    $ 56     $ 1,674     $ 561     $ 936     $ 399     $ 108     $ 3,678     $ 3,734  
Provisions related to sales made in current year period
      310       3,746       753       6,012       213       120       10,844       11,154  
Provisions related to sales made in prior periods
      —        (38 )      33       (29 )      (3 )      (11 )     (48 )     (48 )
Credits and payments
      (295 )      (3,432 )      (701 )      (6,062 )      (168 )      (93 )      (10,456 )      (10,751 ) 
Translation differences
        61       16       18       5       16       116       116  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance at September 30, 2025
    $ 71     $ 2,011     $ 662     $ 875     $ 446     $ 140     $ 4,134     $ 4,205  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
 
 
    
Sales Reserves and Allowances
        
    
Reserves
included in
Accounts
Receivable,
net
    
Rebates
    
Medicaid and
other
governmental
allowances
    
Chargebacks
    
Returns
    
Other
    
Total
reserves
included in
Sales
Reserves
and
Allowances
    
Total
  
    
(U.S.$ in millions)
  
Balance at January 1, 2024
    $ 61     $ 1,603     $ 540     $ 859     $ 436     $ 97     $ 3,535     $ 3,596  
Provisions related to sales made in current year period
      294       3,436       579       5,925       191       146       10,277       10,571  
Provisions related to sales made in prior periods
      —        16       26       (11 )      (28 )      (2 )      1       1  
Credits and payments
      (292 )      (3,269 )      (556 )      (5,877 )      (209 )      (121 )      (10,032 )      (10,324 ) 
Translation differences
      —        1       3       1       (1 )      —        4       4  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Balance at September 30, 2024
    $ 63     $ 1,787     $ 592     $ 897     $ 389     $ 120     $ 3,785     $ 3,848